-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
June 2016
-
Professor Jean-Yves Douillard, MD, PhD
Professor Jean-Yves Douillard has been appointed the first Chief Medical Officer of the European Society of Medical Oncology. Prof. Douillard was previously Professor of Medical Oncology at the Integrated Centres of Oncology R. Gauducheau and University of Nantes Medical School, France, where from 2009–2011, he was Director of Clinical and Translational Research.
-
Paul A. Bunn, Jr, MD
Paul A. Bunn, Jr, received the 2016 David A. Karnofsky Memorial Award and Lecture, which is given annually to an oncologist who has made outstanding contributions to cancer research, diagnosis, and treatment. Dr. Bunn is Distinguished Professor of Medicine and the James Dudley Endowed Professor of Lung Cancer at the University of Colorado School of…
-
Michael R. Blackburn, PhD
Michael R. Blackburn has been appointed Executive Vice President and Chief Academic Officer of The University of Texas Health Science Center at Houston (UTHealth), US. Dr. Blackburn has served as Vice Chairman of the Department of Biochemistry and Molecular Biology at McGovern Medical School at UTHealth since 2011. In 2012, Dr. Blackburn was named joint Dean…
-
Abbas El-Sayed Abbas, MD
Abbas El-Sayed Abbas has been appointed Thoracic Surgeon-in-Chief and Surgical Director of Lung Cancer, Thoracic Malignancy and Foregut Disease Programs for Temple University Health System, Philadelphia, US. Dr. Abbas will continue as Vice Chair of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, Director of Foregut Surgery program, Section Chief…
-
National Comprehensive Cancer Network NSCLC Guideline Updates for 2016: Non-Small Cell Lung Cancer
By Erik J. MacLaren, PhD The table at right lists key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC as of February 2016. These guidelines are not determined solely by evidence, but also incorporate expert opinion and are subject to frequent updates. Recommendations by NCCN fall into 1 of 4 categories of…
-
Best of the 16th World Conference on Lung Cancer in Peru
By Luis E. Raez, MD, FACP, FCCP The International Association for the Study of Lung Cancer (IASLC) and the Peruvian Oncology Research Group (GECO) organized and hosted the “Best of the 16th World Conference on Lung Cancer (WCLC)” in Lima, Peru, on February 4–5 2016. The conference was very successful, with almost 250 doctors attending…
-
Tobacco Control Legislation in the Netherlands
By Prof. Brigit Toebes, PhD, and Willem Bantema, MSc, in collaboration with Wanda de Kanter, MD Critics have warned that Dutch legislation and policy increasingly lag behind that of other countries when it comes to regulating tobacco. There have been criticisms on multiple fronts, including the lack of a firm smoking ban in all (public…
-
7th IASLC Latin American Conference on Lung Cancer
By Nicola M. Parry, DVM From August 25 to 27, 2016, the 7th International Association for the Study of Lung Cancer (IASLC) Latin American Lung Cancer Conference will take place in Panama City, Panama. According to conference chairpersons, Edgardo S. Santos, MD, FACP, Lynn Cancer Institute, Boca Raton, Florida, and Roberto Iván López, MD, Hospital…
-
Interview with Richard Pazdur, MD
New oncology drugs have, for decades, followed a well-trodden path of sequential clinical trials to get from the laboratory to the patient. This model has proven its worth by delivering effective new treatments while also protecting patient safety, but newer “seamless” trial designs have the potential to modernize the drug testing process and allow patients…
-
Q & A with Dr. Laura Bierut
Tobacco smoking dramatically increases the risk of developing lung cancers, and it has long been recognized that nicotine addiction is one of the biggest obstacles to changing current smokers’ behavior. IASLC Lung Cancer News recently spoke with Laura Jean Bierut, MD, Professor of Psychiatry, from the Washington University School of Medicine in St. Louis, Missouri,…
View ILCN Archives
Provider Resources
Popular Articles